Hong Kong · Delayed Price · Currency is HKD Jacobio Pharmaceuticals Group Company Description
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies.
Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under multiple stage studies for indications such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications including NSCLC, PDAC, CRC, and other solid tumors; JAV-8263, a BET inhibitor for solid and liquid tumors; JAB-2485 Aurora A inhibitor, JAB-30355 P53 Y220C inhibitor, JAB-BX102 CD73 mAb inhibitor, JAB-26766 PARP 7 inhibitor, and JAB-BX300 LIF inhibitor under trials for solid tumor indications; and JAB-24114, a glutamine-utilizing enzyme for solid tumor and hematological malignancy indications.
The company also develops IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications.
It has a collaboration agreement with Merck for cetuximab for combination trials. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.
| Country | Cayman Islands |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 257 |
| CEO | Yinxiang Wang |
Contact Details
Address: Building 8 Beijing China | |
| Website | jacobiopharma.com |
Stock Details
| Ticker Symbol | 1167 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG4987A1094 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yinxiang Wang | Executive Chairman and Chief Executive Officer |
| Xiaojie Wang | Executive Director and President of Administration |
| Yunyan Hu | Executive Vice President and Executive Director |
| Tao Yang | Vice President of Human Resources |
| Dr. Andrea Wang-Gillam M.D., Ph.D. | Executive Vice President, Chief Medical Officer and Global Head of Research & Development |
| Yanping Wang | Executive Vice President of Non-Clinical Research & Development |
| Dr. Haijun Wang | Senior Vice President of Information and Data Management |
| Yuli Ding | Executive Vice President of Clinical Development |
| Qing Xue | Joint Company Secretary |
| Ming Fai Chung CPA | Joint Company Secretary |